Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 104OTHER 98FED 3NETWORK 1INDIV 1

Study Type

Observational 3Interventional 1

Sponsor

Conditions

Neoplasms 7Barrett Esophagus 5Carcinoma, Hepatocellular 3Breast Neoplasms 3Multiple Myeloma 2Lymphoma, Follicular 2Lipoma 2Leiomyoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma in Situ 2Warts 1Vaginosis, Bacterial 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Syphilis 1Sexually Transmitted Diseases 1Retroperitoneal liposarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pilonidal Sinus 1Papillomavirus Infections 1Overweight 1Ovarian Neoplasms 1Osteosarcoma 1Obesity 1Neutropenia 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Myasthenia Gravis 1Melanoma 1

Interventions

blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDIV × Interventional × Myasthenia Gravis × Clear all
NCT06836973 2025-03-25

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Da, Yuwei, M.D.

Phase 2/3 Not yet recruiting
2 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡